Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR Agonists & Immunomodulators | DataM Intelligence

According to DataM Intelligence, the Primary Biliary Cholangitis (PBC) Treatment Market reached USD 1.33 billion in 2024 and ...
Healio

VIDEO: New therapies emerging in primary biliary cholangitis

Ahmad Anouti, MD, a pediatric resident at UT Southwestern Medical Center, spoke with Healio about treatments in the primary biliary cholangitis pipeline.He noted one therapy making strides in the ...
EurekAlert!

Gut microbiota: implications in pathogenesis and potential therapeutic target in primary biliary cholangitis

Primary biliary cholangitis (PBC) is a chronic progressive autoimmune disorder characterized by small non-purulent ...
News-Medical.Net on MSN

Blood group A linked to a higher risk of primary biliary cholangitis

Findings indicate blood group A elevates the risk of primary biliary cholangitis, suggesting ABO group analysis could aid in ...
Healio

VIDEO: Elafibranor shows promise as potential treatment for patients with PSC

In this video, Julius Wilder, MD, PhD, discusses early results from the ongoing phase 2 ELMWOOD open-label extension trial of elafibranor in patients with primary sclerosing cholangitis.“Some of the ...
Medscape

Seladelpar Staves Off Liver Stiffness in Primary Biliary Cholangitis

Three-year data from ongoing open-label study supported safety and effectiveness of seladelpar in patients with primary biliary cholangitis.

DataM Intelligence 4 Market Research LLP: Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR Agonists ...

According to DataM Intelligence, the Primary Biliary Cholangitis (PBC) Treatment Market reached USD 1.33 billion in 2024 and is ...